Published • loading... • Updated
Manufacturer of Ozempic, Novo Nordisk Wants to Supply Insulin to SUS and Awaits Bidding
Summary by Agora RN
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
This content was originally published in the Agora RN - Rio Grande do Norte News Portal. Visit https://agorarn.com.br for more Christmas and RN news. Novo Nordisk, manufacturer of Ozempic — a semiglutide-based injection medicine indicated for the treatment of diabetes and obesity — wants to switch to providing human insulin for the Unified Health System (SUS). The company, which maintains a factory in Montes Claros (MG), claims to have the capac…
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
